A study to compare and know the beneficial role of intravenous magnesium sulfate vs placebo as an add on therapy in the treatment of acute exacerbations of chronic obstructive pulmonary disease.
Not Applicable
Completed
- Conditions
- Health Condition 1: null- Acute exacerbations of Chronic Obstructive Pulmonary DiseaseHealth Condition 2: J441- Chronic obstructive pulmonary disease with (acute) exacerbation
- Registration Number
- CTRI/2018/01/011354
- Lead Sponsor
- Kempegowda institute of medical sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 60
Inclusion Criteria
diagnosed with COPD grade 2 and grade 3 (GOLD criteria) presenting with symptoms of acute exacerbations.
Exclusion Criteria
subjects with severe COPD and requiring ventilation in next 2 hours.
subjects with respiratory failure and altered sensorium.
subjects with TB, Bronchiectasis, bronchial asthma.
subjects with clinical evidence of CVA, CAD, Renal dysfunction, uncontrolled Diabetes Mellitus.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method asses the efficacy of Magnesium sulfate infusion by monitoring the changes in PEFR from baselineTimepoint: asses the efficacy of Magnesium sulfate infusion by monitoring the changes in PEFR at 0,15,30 and 45 minutes from baseline
- Secondary Outcome Measures
Name Time Method to asses the safety and tolerability of IV magnesium sulfate based on adverse effects. <br/ ><br>To calculate the cost effectiveness of magnesium sulfateTimepoint: at the end of the study